|
23 Oct 2020 |
Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)
|
|
23 Oct 2020 |
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
|
|
23 Oct 2020 |
Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases
|
|
23 Oct 2020 |
U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
|
|
22 Oct 2020 |
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
|
|
22 Oct 2020 |
Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19
|
|
22 Oct 2020 |
STORM Therapeutics selects first-in-class clinical candidate targeting METTL3
|
|
22 Oct 2020 |
Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients
|
|
22 Oct 2020 |
Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)
|
|
22 Oct 2020 |
UCB’s anti-epileptic drug VIMPAT[®] (lacosamide) receives EU CHMP positive opinion for primary generalised tonic-clonic seizures
|
|
22 Oct 2020 |
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells
|
|
22 Oct 2020 |
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
|
|
22 Oct 2020 |
ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Novel COVID-19 Vaccine Candidate hAd5
|
|
22 Oct 2020 |
GSK presents positive clinical data on maternal and older adults RSV candidate vaccines
|
|
21 Oct 2020 |
Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Novo Nordisk
|
|
21 Oct 2020 |
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
|
|
21 Oct 2020 |
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19
|
|
21 Oct 2020 |
Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)
|
|
21 Oct 2020 |
Valneva Announces Positive Initial Results for Second Phase 2 Study of Lyme Disease Vaccine Candidate VLA15
|
|
21 Oct 2020 |
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies
|
